{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:33:58Z","timestamp":1784082838567,"version":"3.55.0"},"reference-count":108,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2020,1,15]]},"abstract":"<jats:sec><jats:title>:<\/jats:title><jats:p>Alzheimer's disease is a progressive neurodegenerative disorder that affects the central nervous system. There are several factors that cause AD, like, intracellular hyperphosphorylated Tau tangles, collection of extracellular Amyloid-\u03b242 and generation of reactive oxygen species due to mitochondrial dysfunction. This review analyses the most active target of AD and both types of AD-like early-onset AD and late-onset AD. BACE1 is a \u03b2-secretase involved in the cleavage of amyloid precursor protein and the pathogenesis of Alzheimer's disease. The presenilin proteins play a critical role in the pathogenesis of Alzheimer malady by intervening the intramembranous cleavage of amyloid precursor protein and the generation of amyloid \u03b2. The two homologous proteins PS1 and PS2 speak to the reactant subunits of particular \u03b3-secretase edifices that intercede an assortment of cellular processes. Natural products are common molecular platforms in drug development in AD. Many natural products are being tested in various animal model systems for their role as a potential therapeutic target in AD. Presently, there are a few theories clarifying the early mechanisms of AD pathogenesis. Recently, research advancements in the field of nanotechnology, which utilize macromolecular strategies to make drugs in nanoscale measurements, offer nanotechnology-based diagnostic tools and drug carriers which are highly sensitive for effective drug targeting in the treatment of Alzheimer\u2019s disease.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1871527318666191011145941","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T09:22:06Z","timestamp":1571044926000},"page":"657-667","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Structure and Function of \u03b1, \u03b2 and \u03b3-Secretase as Therapeutic Target Enzymes in the Development of Alzheimer\u2019s Disease: A Review"],"prefix":"10.2174","volume":"18","author":[{"given":"Syed S.","family":"Ahmad","sequence":"first","affiliation":[{"name":"Department of Bioengineering, Faculty of Engineering, Integral University, Lucknow, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Khan","sequence":"additional","affiliation":[{"name":"Wuhan University, School of Medicine, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A.","family":"Kamal","sequence":"additional","affiliation":[{"name":"King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 80216, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umam","family":"Wasi","sequence":"additional","affiliation":[{"name":"Department of Biosciences, Faculty of Science, Integral University, Lucknow, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.3390\/ijms19123702","volume":"19","author":"Femminella G.D.","year":"2018","unstructured":"Femminella G.D.; Thayanandan T.; Calsolaro V.; Imaging and molecular mechanisms of Alzheimer\u2019s disease: A review. Int J Mol Sci 2018,19(12),3702","journal-title":"Int J Mol Sci"},{"key":"ref=2","author":"Prince M.","year":"2015","unstructured":"Prince M.; Wimo A.; Guerchet M.; Ali G.; Wu Y.; Prina M.; World Alzheimer Report-The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends; Alzheimer\u2019s Disease International [cited: 15 October 2004]; Available from:2015","journal-title":"World Alzheimer Report-The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends; Alzheimer\u2019s Disease International"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2018.02.001","volume":"14","year":"2018","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement Alzheimer\u2019s Association2018,14,367-429","journal-title":"Alzheimers Dement"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2174\/1573409913666170414123825","volume":"13","author":"Ahmad SS","year":"2017","unstructured":"Ahmad SS; Akhtar S; Screening and elucidation of selected natural compounds for anti- Alzheimer\u2019s potential targeting BACE-1 enzyme: A case computational study. Curr Comput Aided Drug Des Danish Rizvi SM, et al.2017,13(4),311-318","journal-title":"Curr Comput Aided Drug Des"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.neubiorev.2011.03.001","volume":"35","author":"Craig L.A.","year":"2011","unstructured":"Craig L.A.; Hong N.S.; McDonald R.J.; Revisiting the cholinergic hypothesis in the development of Alzheimer\u2019s disease. Neurosci Biobehav Rev 2011,35(6),1397-1409","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"Karran E.","year":"2011","unstructured":"Karran E.; Mercken M.; De Strooper B.; The amyloid cascade hypothesis for Alzheimer\u2019s disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 2011,10(9),698-712","journal-title":"Nat Rev Drug Discov"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.arcmed.2010.03.007","volume":"41","author":"Maccioni R.B.","year":"2010","unstructured":"Maccioni R.B.; Far\u00edas G.; Morales I.; Navarrete L.; The revitalized tau hypothesis on Alzheimer\u2019s disease. Arch Med Res 2010,41(3),226-231","journal-title":"Arch Med Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0891-5849(96)00629-6","volume":"23","author":"Markesbery W.R.","year":"1997","unstructured":"Markesbery W.R.; Oxidative stress hypothesis in Alzheimer\u2019s disease. Free Radic Biol Med 1997,23(1),134-147","journal-title":"Free Radic Biol Med"},{"key":"ref=9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033552","volume":"7","author":"Craddock T.J.","year":"2012","unstructured":"Craddock T.J.; Tuszynski J.A.; Chopra D.; The zinc dyshomeostasis hypothesis of Alzheimer\u2019s disease. PLoS One 2012,7(3)","journal-title":"PLoS One"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2013.02.004","volume":"105","author":"Yamashima T.","year":"2013","unstructured":"Yamashima T.; Reconsider Alzheimer\u2019s disease by the \u2018calpain-cathepsin hypothesis\u2019--a perspective review. Prog Neurobiol 2013,105,1-23","journal-title":"Prog Neurobiol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.2174\/1871527315666161003165855","volume":"15","author":"Ahmad S.S.","year":"2016","unstructured":"Ahmad S.S.; Akhtar S.; Jamal Q.M.; Multiple targets for the management of Alzheimer\u2019s disease. CNS Neurol Disord Drug Targets 2016,15(10),1279-1289","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/ncpneuro0294","volume":"2","author":"Selnes O.A.","year":"2006","unstructured":"Selnes O.A.; Vinters H.V.; Vascular cognitive impairment. Nat Clin Pract Neurol 2006,2(10),538-547","journal-title":"Nat Clin Pract Neurol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1097\/nen.0b013e31815c5efb","volume":"66","author":"Nelson P.T.","year":"2007","unstructured":"Nelson P.T.; Jicha G.A.; Schmitt F.A.; Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: Neuritic plaques and neurofibrillary tangles \u201cdo count\u201d when staging disease severity. J Neuropathol Exp Neurol 2007,66(12),1136-1146","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"12787","DOI":"10.1523\/JNEUROSCI.3657-09.2009","volume":"29","author":"Vassar R.","year":"2009","unstructured":"Vassar R.; Kovacs D.M.; Yan R.; Wong P.C.; The \u03b2-secretase enzyme BACE in health and Alzheimer\u2019s disease: Regulation, cell biology, function, and therapeutic potential. J Neurosci 2009,29(41),12787-12794","journal-title":"J Neurosci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2125.2010.03830.x","volume":"71","author":"Akter K.","year":"2011","unstructured":"Akter K.; Lanza E.A.; Martin S.A.; Myronyuk N.; Rua M.; Raffa R.B.; Diabetes mellitus and Alzheimer\u2019s disease: Shared pathology and treatment? Br J Clin Pharmacol 2011,71(3),365-376","journal-title":"Br J Clin Pharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nrn2420","volume":"9","author":"G\u00f6tz J.","year":"2008","unstructured":"G\u00f6tz J.; Ittner L.M.; Animal models of Alzheimer\u2019s disease and frontotemporal dementia. Nat Rev Neurosci 2008,9(7),532-544","journal-title":"Nat Rev Neurosci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/01.wad.0000127495.10774.a4","volume":"18","author":"Winblad B.","year":"2004","unstructured":"Winblad B.; Jelic V.; Long-term treatment of Alzheimer disease: Efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis Assoc Disord 2004,18(Suppl. 1),S2-S8","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00018-009-9070-1","volume":"66","author":"G\u00f6tz J.","year":"2009","unstructured":"G\u00f6tz J.; Ittner L.M.; Lim Y.A.; Common features between diabetes mellitus and Alzheimer\u2019s disease. Cell Mol Life Sci 2009,66(8),1321-1325","journal-title":"Cell Mol Life Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1212\/WNL.36.9.1226","volume":"36","author":"Hauser W.A.","year":"1986","unstructured":"Hauser W.A.; Morris M.L.; Heston L.L.; Anderson V.E.; Seizures and myoclonus in patients with Alzheimer\u2019s disease. Neurology 1986,36(9),1226-1230","journal-title":"Neurology"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ajmg.b.32499","volume":"174","author":"Naj A.C.","year":"2017","unstructured":"Naj A.C.; Schellenberg G.D.; Alzheimer\u2019s Disease Genetics Consortium (ADGC). Genomic variants, genes, and pathways of Alzheimer\u2019s disease: An overview. Am J Med Genet B Neuropsychiatr Genet 2017,174(1),5-26","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/349704a0","volume":"349","author":"Goate A.","year":"1991","unstructured":"Goate A.; Chartier-Harlin M.C.; Mullan M.; Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature 1991,349(6311),704-706","journal-title":"Nature"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.7638622","volume":"269","author":"Levy-Lahad E.","year":"1995","unstructured":"Levy-Lahad E.; Wasco W.; Poorkaj P.; Candidate gene for the chromosome 1 familial Alzheimer\u2019s disease locus. Science 1995,269(5226),973-977","journal-title":"Science"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/376775a0","volume":"376","author":"Rogaev E.I.","year":"1995","unstructured":"Rogaev E.I.; Sherrington R.; Rogaeva E.A.; Familial Alzheimer\u2019s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer\u2019s disease type 3 gene. Nature 1995,376(6543),775-778","journal-title":"Nature"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/375754a0","volume":"375","author":"Sherrington R.","year":"1995","unstructured":"Sherrington R.; Rogaev E.I.; Liang Y.; Cloning of a gene bearing missense mutations in early-onset familial Alzheimer\u2019s disease. Nature 1995,375(6534),754-760","journal-title":"Nature"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"8098","DOI":"10.1073\/pnas.90.17.8098","volume":"90","author":"Strittmatter W.J.","year":"1993","unstructured":"Strittmatter W.J.; Weisgraber K.H.; Huang D.Y.; Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993,90(17),8098-8102","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s004060050101","volume":"249","author":"F\u00f6rstl H.","year":"1999","unstructured":"F\u00f6rstl H.; Kurz A.; Clinical features of Alzheimer\u2019s disease. Eur Arch Psychiatry Clin Neurosci 1999,249(6),288-290","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref=27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015746","volume":"7","author":"Bature F.","year":"2017","unstructured":"Bature F.; Guinn B.A.; Pang D.; Pappas Y.; Signs and symptoms preceding the diagnosis of Alzheimer\u2019s disease: A systematic scoping review of literature from 1937 to 2016. BMJ Open 2017,7(8)","journal-title":"BMJ Open"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"6764","DOI":"10.1523\/JNEUROSCI.5794-10.2011","volume":"31","author":"Braskie M.N.","year":"2011","unstructured":"Braskie M.N.; Jahanshad N.; Stein J.L.; Common Alzheimer\u2019s disease risk variant within the CLU gene affects white matter microstructure in young adults. J Neurosci 2011,31(18),6764-6770","journal-title":"J Neurosci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/brain\/awu046","volume":"137","author":"Shinohara M.","year":"2014","unstructured":"Shinohara M.; Fujioka S.; Murray M.E.; Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer\u2019s disease. Brain 2014,137(Pt 5),1533-1549","journal-title":"Brain"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2174\/138920207783769512","volume":"8","author":"Cole S.L.","year":"2007","unstructured":"Cole S.L.; Vassar R.; The basic biology of BACE1: A key therapeutic target for Alzheimer\u2019s disease. Curr Genomics 2007,8(8),509-530","journal-title":"Curr Genomics"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/361260a0","volume":"361","author":"Seubert P.","year":"1993","unstructured":"Seubert P.; Oltersdorf T.; Lee M.G.; Secretion of \u03b2-amyloid precursor protein cleaved at the amino terminus of the \u03b2-amyloid peptide. Nature 1993,361(6409),260-263","journal-title":"Nature"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/359322a0","volume":"359","author":"Haass C.","year":"1992","unstructured":"Haass C.; Schlossmacher M.G.; Hung A.Y.; Amyloid \u03b2-peptide is produced by cultured cells during normal metabolism. Nature 1992,359(6393),322-325","journal-title":"Nature"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1126\/science.286.5440.735","volume":"286","author":"Vassar R.","year":"1999","unstructured":"Vassar R.; Bennett B.D.; Babu-Khan S.; Beta-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999,286(5440),735-741","journal-title":"Science"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1046\/j.1471-4159.2000.0752133.x","volume":"75","author":"Marcinkiewicz M.","year":"2000","unstructured":"Marcinkiewicz M.; Seidah N.G.; Coordinated expression of \u03b2-amyloid precursor protein and the putative \u03b2-secretase BACE and \u03b1-secretase ADAM10 in mouse and human brain. J Neurochem 2000,75(5),2133-2143","journal-title":"J Neurochem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"12787","DOI":"10.1523\/JNEUROSCI.3657-09.2009","volume":"29","author":"Vassar R.","year":"2009","unstructured":"Vassar R.; Kovacs D.M.; Yan R.; Wong P.C.; The \u03b2-secretase enzyme BACE in health and Alzheimer\u2019s disease: Regulation, cell biology, function, and therapeutic potential. J Neurosci 2009,29(41),12787-12794","journal-title":"J Neurosci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"Selkoe D.J.","year":"2016","unstructured":"Selkoe D.J.; Hardy J.; The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 2016,8(6),595-608","journal-title":"EMBO Mol Med"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.3390\/ijms19123702","volume":"19","author":"Femminella G.D.","year":"2018","unstructured":"Femminella G.D.; Thayanandan T.; Calsolaro V.; Imaging and molecular mechanisms of Alzheimer\u2019s Disease: A review. Int J Mol Sci 2018,19(12),3702","journal-title":"Int J Mol Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"Scheltens P.","year":"2016","unstructured":"Scheltens P.; Blennow K.; Breteler M.M.; Alzheimer\u2019s disease. Lancet 2016,388(10043),505-517","journal-title":"Lancet"},{"key":"ref=39","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006270","volume":"2","author":"Haass C.","year":"2012","unstructured":"Haass C.; Kaether C.; Thinakaran G.; Sisodia S.; Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2012,2(5)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.brainresbull.2016.08.009","volume":"133","author":"Wilkins H.M.","year":"2017","unstructured":"Wilkins H.M.; Swerdlow R.H.; Amyloid precursor protein processing and bioenergetics. Brain Res Bull 2017,133,71-79","journal-title":"Brain Res Bull"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1074\/jbc.270.8.3565","volume":"270","author":"Lai A.","year":"1995","unstructured":"Lai A.; Sisodia S.S.; Trowbridge I.S.; Characterization of sorting signals in the beta-amyloid precursor protein cytoplasmic domain. J Biol Chem 1995,270(8),3565-3573","journal-title":"J Biol Chem"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fncel.2015.00109","volume":"9","author":"La Rosa L.R.","year":"2015","unstructured":"La Rosa L.R.; Perrone L.; Nielsen M.S.; Calissano P.; Andersen O.M.; Matrone C.; Y682G mutation of amyloid precursor protein promotes endo-lysosomal dysfunction by disrupting APP-SorLA interaction. Front Cell Neurosci 2015,9,109","journal-title":"Front Cell Neurosci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"18851","DOI":"10.1074\/jbc.274.27.18851","volume":"274","author":"Perez R.G.","year":"1999","unstructured":"Perez R.G.; Soriano S.; Hayes J.D.; Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abeta42. J Biol Chem 1999,274(27),18851-18856","journal-title":"J Biol Chem"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1756-6606-4-3","volume":"4","author":"Zhang Y.W.","year":"2011","unstructured":"Zhang Y.W.; Thompson R.; Zhang H.; Xu H.; APP processing in Alzheimer\u2019s disease. Mol Brain 2011,4,3","journal-title":"Mol Brain"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"Chen G.F.","year":"2017","unstructured":"Chen G.F.; Xu T.H.; Yan Y.; Amyloid beta: Structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 2017,38(9),1205-1235","journal-title":"Acta Pharmacol Sin"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1016\/S0021-9258(18)53650-4","volume":"268","author":"Haass C.","year":"1993","unstructured":"Haass C.; Hung A.Y.; Schlossmacher M.G.; Teplow D.B.; Selkoe D.J.; Beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J Biol Chem 1993,268(5),3021-3024","journal-title":"J Biol Chem"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1073\/pnas.96.7.3922","volume":"96","author":"Lammich S.","year":"1999","unstructured":"Lammich S.; Kojro E.; Postina R.; Constitutive and regulated alpha-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 1999,96(7),3922-3927","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1046\/j.1471-4159.1996.67051882.x","volume":"67","author":"Furukawa K.","year":"1996","unstructured":"Furukawa K.; Sopher B.L.; Rydel R.E.; Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J Neurochem 1996,67(5),1882-1896","journal-title":"J Neurochem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1074\/jbc.275.4.2568","volume":"275","author":"Skovronsky D.M.","year":"2000","unstructured":"Skovronsky D.M.; Moore D.B.; Milla M.E.; Doms R.W.; Lee V.M.; Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-Golgi network. J Biol Chem 2000,275(4),2568-2575","journal-title":"J Biol Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","volume":"6","author":"De Strooper B.","year":"2010","unstructured":"De Strooper B.; Vassar R.; Golde T.; The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010,6(2),99-107","journal-title":"Nat Rev Neurol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.2174\/092986707782360060","volume":"14","author":"Bandyopadhyay S.","year":"2007","unstructured":"Bandyopadhyay S.; Goldstein L.E.; Lahiri D.K.; Rogers J.T.; Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer\u2019s disease. Curr Med Chem 2007,14(27),2848-2864","journal-title":"Curr Med Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2047-9158-1-21","volume":"1","author":"Hong-Qi Y.","year":"2012","unstructured":"Hong-Qi Y.; Zhi-Kun S.; Sheng-Di C.; Current advances in the treatment of Alzheimer\u2019s disease: Focused on considerations targeting A\u03b2 and tau. Transl Neurodegener 2012,1(1),21","journal-title":"Transl Neurodegener"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1242\/jcs.113.11.1857","volume":"113","author":"De Strooper B.","year":"2000","unstructured":"De Strooper B.; Annaert W.; Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 2000,113(Pt 11),1857-1870","journal-title":"J Cell Sci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"FSO11","DOI":"10.4155\/fso.15.9","volume":"1","author":"MacLeod R.","year":"2015","unstructured":"MacLeod R.; Hillert E.K.; Cameron R.T.; Baillie G.S.; The role and therapeutic targeting of \u03b1-, \u03b2- and \u03b3-secretase in Alzheimer\u2019s disease. Future Sci OA 2015,1(3),FSO11","journal-title":"Future Sci OA"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0896-6273(00)80291-3","volume":"17","author":"Thinakaran G.","year":"1996","unstructured":"Thinakaran G.; Borchelt D.R.; Lee M.K.; Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron 1996,17(1),181-190","journal-title":"Neuron"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/35041097","volume":"2","author":"Steiner H.","year":"2000","unstructured":"Steiner H.; Kostka M.; Romig H.; Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases. Nat Cell Biol 2000,2(11),848-851","journal-title":"Nat Cell Biol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"35113","DOI":"10.1074\/jbc.M204446200","volume":"277","author":"Kimberly W.T.","year":"2002","unstructured":"Kimberly W.T.; LaVoie M.J.; Ostaszewski B.L.; Ye W.; Wolfe M.S.; Selkoe D.J.; Complex N-linked glycosylated nicastrin associates with active gamma-secretase and undergoes tight cellular regulation. J Biol Chem 2002,277(38),35113-35117","journal-title":"J Biol Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1073\/pnas.022523499","volume":"99","author":"Goutte C.","year":"2002","unstructured":"Goutte C.; Tsunozaki M.; Hale V.A.; Priess J.R.; APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci USA 2002,99(2),775-779","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1534-5807(02)00189-2","volume":"3","author":"Francis R.","year":"2002","unstructured":"Francis R.; McGrath G.; Zhang J.; APH-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell 2002,3(1),85-97","journal-title":"Dev Cell"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.nbd.2004.08.002","volume":"17","author":"H\u00e9bert S.S.","year":"2004","unstructured":"H\u00e9bert S.S.; Serneels L.; Dejaegere T.; Coordinated and widespread expression of \u03b3-secretase in vivo: Evidence for size and molecular heterogeneity. Neurobiol Dis 2004,17(2),260-272","journal-title":"Neurobiol Dis"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bbrc.2004.11.130","volume":"327","author":"Saito S.","year":"2005","unstructured":"Saito S.; Araki W.; Expression profiles of two human APH-1 genes and their roles in formation of presenilin complexes. Biochem Biophys Res Commun 2005,327(1),18-22","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1073\/pnas.052436599","volume":"99","author":"Esler W.P.","year":"2002","unstructured":"Esler W.P.; Kimberly W.T.; Ostaszewski B.L.; Activity-dependent isolation of the presenilin-gamma-secretase complex reveals nicastrin and a gamma substrate. Proc Natl Acad Sci USA 2002,99(5),2720-2725","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0896-6273(00)80230-5","volume":"17","author":"Borchelt D.R.","year":"1996","unstructured":"Borchelt D.R.; Thinakaran G.; Eckman C.B.; Familial Alzheimer\u2019s disease-linked presenilin 1 variants elevate Abeta1-42\/1-40 ratio in vitro and in vivo. Neuron 1996,17(5),1005-1013","journal-title":"Neuron"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ncl.2007.03.009","volume":"25","author":"Ertekin-Taner N.","year":"2007","unstructured":"Ertekin-Taner N.; Genetics of Alzheimer\u2019s disease: A centennial review. Neurol Clin 2007,25(3),611-667","journal-title":"Neurol Clin"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/sj.embor.7400784","volume":"7","author":"Radde R.","year":"2006","unstructured":"Radde R.; Bolmont T.; Kaeser S.A.; Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006,7(9),940-946","journal-title":"EMBO Rep"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"Doody R.S.","year":"2014","unstructured":"Doody R.S.; Farlow M.; Aisen P.S.; Alzheimer\u2019s disease cooperative study data analysis and publication committee. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer\u2019s disease. N Engl J Med 2014,370(15),1460","journal-title":"N Engl J Med"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"Salloway S.","year":"2014","unstructured":"Salloway S.; Sperling R.; Fox N.C.; Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med Bapineuzumab 301 and 302 Clinical Trial Investigators2014,370(4),322-333","journal-title":"N Engl J Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ejmech.2019.02.030","volume":"167","author":"Sharma P.","year":"2019","unstructured":"Sharma P.; Tripathi A.; Tripathi P.N.; Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 2019,167,510-524","journal-title":"Eur J Med Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1002\/med.21563","volume":"39","author":"Schaduangrat N.","year":"2019","unstructured":"Schaduangrat N.; Prachayasittikul V.; Choomwattana S.; Multidisciplinary approaches for targeting the secretase protein family as a therapeutic route for Alzheimer\u2019s disease. Med Res Rev 2019,39(5),1730-1778","journal-title":"Med Res Rev"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.2174\/1568026615666150506151101","volume":"15","author":"Prachayasittikul V.","year":"2015","unstructured":"Prachayasittikul V.; Worachartcheewan A.; Shoombuatong W.; Computer-aided drug design of bioactive natural products. Curr Top Med Chem 2015,15(18),1780-1800","journal-title":"Curr Top Med Chem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"608","DOI":"10.2174\/1871527317666180724150839","volume":"17","author":"Jiang X.W.","year":"2018","unstructured":"Jiang X.W.; Lu H.Y.; Xu Z.; In silico analyses for key genes and molecular genetic mechanism in epilepsy and Alzheimer\u2019s disease. CNS Neurol Disord Drug Targets 2018,17(8),608-617","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2174\/1871527317666180627122448","volume":"17","author":"Singh A.","year":"2018","unstructured":"Singh A.; Hasan A.; Tiwari S.; Pandey L.M.; Therapeutic advancement in Alzheimer disease: New hopes on the horizon? CNS Neurol Disord Drug Targets 2018,17(8),571-589","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2174\/1871527317666180115162422","volume":"17","author":"Iman K.","year":"2018","unstructured":"Iman K.; Mirza M.U.; Mazhar N.; Vanmeert M.; Irshad I.; Kamal M.A.; In silico structure-based identification of novel acetylcholinesterase inhibitors against Alzheimer\u2019s disease. CNS Neurol Disord Drug Targets 2018,17(1),54-68","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.phymed.2006.09.003","volume":"14","author":"Jeon S.Y.","year":"2007","unstructured":"Jeon S.Y.; Kwon S.H.; Seong Y.H.; \u03b2-secretase (BACE1)-inhibiting stilbenoids from Smilax rhizoma. Phytomedicine 2007,14(6),403-408","journal-title":"Phytomedicine"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1016\/j.bmcl.2003.09.018","volume":"13","author":"Jeon S.Y.","year":"2003","unstructured":"Jeon S.Y.; Bae K.; Seong Y.H.; Song K.S.; Green tea catechins as a BACE1 (beta-secretase) inhibitor. Bioorg Med Chem Lett 2003,13(22),3905-3908","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.bmc.2011.12.002","volume":"20","author":"Marumoto S.","year":"2012","unstructured":"Marumoto S.; Miyazawa M.; Structure-activity relationships for naturally occurring coumarins as \u03b2-secretase inhibitor. Bioorg Med Chem 2012,20(2),784-788","journal-title":"Bioorg Med Chem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.lfs.2010.08.005","volume":"87","author":"Jung H.A.","year":"2010","unstructured":"Jung H.A.; Jin S.E.; Choi R.J.; Anti-amnesic activity of neferine with antioxidant and anti-inflammatory capacities, as well as inhibition of ChEs and BACE1. Life Sci 2010,87(13-14),420-430","journal-title":"Life Sci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1055\/s-2004-815491","volume":"70","author":"Park I.H.","year":"2004","unstructured":"Park I.H.; Jeon S.Y.; Lee H.J.; Kim S.I.; Song K.S.; A \u03b2-secretase (BACE1) inhibitor hispidin from the mycelial cultures of Phellinus linteus. Planta Med 2004,70(2),143-146","journal-title":"Planta Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/nu9090973","volume":"9","author":"Youn K.","year":"2017","unstructured":"Youn K.; Yu Y.; Lee J.; Jeong W.S.; Ho C.T.; Jun M.; Polymethoxyflavones: Novel \u03b2-secretase (BACE1) inhibitors from citrus peels. Nutrients 2017,9(9),973","journal-title":"Nutrients"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1089\/jmf.2017.4068","volume":"21","author":"Youn K.","year":"2018","unstructured":"Youn K.; Park J.H.; Lee S.; BACE1 inhibition by Genistein: Biological evaluation, kinetic analysis, and molecular docking simulation. J Med Food 2018,21(4),416-420","journal-title":"J Med Food"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12868-017-0394-8","volume":"18","author":"Kumar S.","year":"2017","unstructured":"Kumar S.; Chowdhury S.; Kumar S.; In silico repurposing of antipsychotic drugs for Alzheimer\u2019s disease. BMC Neurosci 2017,18(1),76","journal-title":"BMC Neurosci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12929-017-0355-7","volume":"24","author":"Hung S.Y.","year":"2017","unstructured":"Hung S.Y.; Fu W.M.; Drug candidates in clinical trials for Alzheimer\u2019s disease. J Biomed Sci 2017,24(1),47","journal-title":"J Biomed Sci"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2174\/1871527317666180525113109","volume":"17","author":"Wang K.","year":"2018","unstructured":"Wang K.; Sun W.; Zhang L.; Oleanolic acid ameliorates A\u03b225-35 injection-induced memory deficit in Alzheimer\u2019s disease model rats by maintaining synaptic plasticity. CNS Neurol Disord Drug Targets 2018,17(5),389-399","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1871527317666180508123050","volume":"17","author":"Beg T.","year":"2018","unstructured":"Beg T.; Jyoti S.; Naz F.; Protective effect of Kaempferol on the transgenic drosophila model of Alzheimer\u2019s disease. CNS Neurol Disord Drug Targets 2018,17(6),421-429","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2174\/1871527317666180309130912","volume":"17","author":"Bais S.","year":"2018","unstructured":"Bais S.; Kumari R.; Prashar Y.; Ameliorative effect of trans-sinapic acid and its protective role in cerebral hypoxia in aluminium chloride induced dementia of Alzheimer\u2019s type. CNS Neurol Disord Drug Targets 2018,17(2),144-154","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=86","volume":"4","author":"Xinyu D.","year":"2018","unstructured":"Xinyu D.; Yuntao L.; Yuejiao Z.; Recent developments of nanotechnology for Alzheimer\u2019s disease diagnosis and therapy. Glob J Nano 2018,4(4)","journal-title":"Glob J Nano"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.2174\/1567205014666170203125008","volume":"14","author":"Leszek J.","year":"2017","unstructured":"Leszek J.; Md Ashraf G.; Tse W.H.; Nanotechnology for Alzheimer disease. Curr Alzheimer Res 2017,14(11),1182-1189","journal-title":"Curr Alzheimer Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/17512433.2017.1324781","volume":"10","author":"Naz\u0131ro\u011flu M.","year":"2017","unstructured":"Naz\u0131ro\u011flu M.; Muhamad S.; Pecze L.; Nanoparticles as potential clinical therapeutic agents in Alzheimer\u2019s disease: Focus on selenium nanoparticles. Expert Rev Clin Pharmacol 2017,10(7),773-782","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2217\/nnm.14.206","volume":"10","author":"Gregori M.","year":"2015","unstructured":"Gregori M.; Masserini M.; Mancini S.; Nanomedicine for the treatment of Alzheimer\u2019s disease. Nanomedicine (Lond) 2015,10(7),1203-1218","journal-title":"Nanomedicine (Lond)"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.bcp.2012.11.014","volume":"85","author":"Mullane K.","year":"2013","unstructured":"Mullane K.; Williams M.; Alzheimer\u2019s therapeutics: Continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol 2013,85(3),289-305","journal-title":"Biochem Pharmacol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jconrel.2015.03.024","volume":"206","author":"Lauzon M.A.","year":"2015","unstructured":"Lauzon M.A.; Daviau A.; Marcos B.; Faucheux N.; Nanoparticle-mediated growth factor delivery systems: A new way to treat Alzheimer\u2019s disease. J Control Release 2015,206,187-205","journal-title":"J Control Release"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","volume":"16","author":"Ballabh P.","year":"2004","unstructured":"Ballabh P.; Braun A.; Nedergaard M.; The blood-brain barrier: An overview: Structure, regulation, and clinical implications. Neurobiol Dis 2004,16(1),1-13","journal-title":"Neurobiol Dis"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jconrel.2003.08.006","volume":"93","author":"Lockman P.R.","year":"2003","unstructured":"Lockman P.R.; Oyewumi M.O.; Koziara J.M.; Roder K.E.; Mumper R.J.; Allen D.D.; Brain uptake of thiamine-coated nanoparticles. J Control Release 2003,93(3),271-282","journal-title":"J Control Release"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.bbrc.2010.02.046","volume":"393","author":"Lasagna-Reeves C.","year":"2010","unstructured":"Lasagna-Reeves C.; Gonzalez-Romero D.; Barria M.A.; Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem Biophys Res Commun 2010,393(4),649-655","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2217\/nnm.09.29","volume":"4","author":"Wilson B.","year":"2009","unstructured":"Wilson B.; Brain targeting PBCA nanoparticles and the blood-brain barrier. Nanomedicine (Lond) 2009,4(5),499-502","journal-title":"Nanomedicine (Lond)"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/17425247.2016.1178237","volume":"13","author":"Cacciatore I.","year":"2016","unstructured":"Cacciatore I.; Ciulla M.; Fornasari E.; Marinelli L.; Di Stefano A.; Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Expert Opin Drug Deliv 2016,13(8),1121-1131","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1002\/jps.24557","volume":"104","author":"Elnaggar Y.S.R.","year":"2015","unstructured":"Elnaggar Y.S.R.; Etman S.M.; Abdelmonsif D.A.; Abdallah O.Y.; Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer\u2019s disease: Optimization, biological efficacy, and potential toxicity. J Pharm Sci 2015,104,3544-3556","journal-title":"J Pharm Sci"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S0753-3322(01)00060-9","volume":"55","author":"Sinha J.","year":"2001","unstructured":"Sinha J.; Das N.; Basu M.K.; Liposomal antioxidants in combating ischemia-reperfusion injury in rat brain. Biomed Pharmacother 2001,55(5),264-271","journal-title":"Biomed Pharmacother"},{"key":"ref=99","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201807965","volume":"31","author":"Kim D.","year":"2019","unstructured":"Kim D.; Kwon H.J.; Hyeon T.; Magnetite\/ceria nanoparticle assemblies for extracorporeal cleansing of amyloid-\u03b2 in Alzheimer\u2019s disease. Adv Mater 2019,31(19)","journal-title":"Adv Mater"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/jphp.12836","volume":"70","author":"Wong L.R.","year":"2018","unstructured":"Wong L.R.; Ho P.C.; Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: Implications for the treatment of Alzheimer\u2019s disease. J Pharm Pharmacol 2018,70(1),59-69","journal-title":"J Pharm Pharmacol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.tibtech.2017.06.002","volume":"35","author":"Hajipour M.J.","year":"2017","unstructured":"Hajipour M.J.; Santoso M.R.; Rezaee F.; Aghaverdi H.; Mahmoudi M.; Perry G.; Advances in Alzheimer\u2019s diagnosis and therapy: The implications of nanotechnology. Trends Biotechnol 2017,35(10),937-953","journal-title":"Trends Biotechnol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1289\/ehp.8871","volume":"114","author":"Gwinn M.R.","year":"2006","unstructured":"Gwinn M.R.; Vallyathan V.; Nanoparticles: Health effects--pros and cons. Environ Health Perspect 2006,114(12),1818-1825","journal-title":"Environ Health Perspect"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.bios.2016.01.065","volume":"80","author":"Kaushik A.","year":"2016","unstructured":"Kaushik A.; Jayant R.D.; Tiwari S.; Vashist A.; Nair M.; Nano-biosensors to detect beta-amyloid for Alzheimer\u2019s disease management. Biosens Bioelectron 2016,80,273-287","journal-title":"Biosens Bioelectron"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1007\/s00044-016-1594-y","volume":"25","author":"Verma A.","year":"2016","unstructured":"Verma A.; Kumar A.; Debnath M.; Molecular docking and simulation studies to give insight of surfactin amyloid interaction for destabilizing Alzheimer\u2019s A\u03b242 protofibrils. Med Chem Res 2016,25,1616-1622","journal-title":"Med Chem Res"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.2174\/1567205014666170508121031","volume":"14","author":"Ahmad J.","year":"2017","unstructured":"Ahmad J.; Akhter S.; Rizwanullah M.; Nanotechnology based theranostic approaches in Alzheimer\u2019s disease management: Current status and future perspective. Curr Alzheimer Res 2017,14(11),1164-1181","journal-title":"Curr Alzheimer Res"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.4103\/1673-5374.239449","volume":"13","author":"Li M.Z.","year":"2018","unstructured":"Li M.Z.; Zheng L.J.; Shen J.; SIRT1 facilitates amyloid beta peptide degradation by upregulating lysosome number in primary astrocytes. Neural Regen Res 2018,13(11),2005-2013","journal-title":"Neural Regen Res"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3389\/fnins.2018.00778","volume":"12","author":"Fujita Y.","year":"2018","unstructured":"Fujita Y.; Yamashita T.; Sirtuins in neuroendocrine regulation and neurological diseases. Front Neurosci 2018,12,778","journal-title":"Front Neurosci"},{"key":"ref=108","first-page":"1","volume":"2","author":"Martins I.J.","year":"2019","unstructured":"Martins I.J.; Appetite regulation and the peripheral sink amyloid beta clearance pathway in diabetes and Alzheimer\u2019s disease. Top 10 Commentaries in Alzheimer\u2019s Disease 2019,2,1-11","journal-title":"Top 10 Commentaries in Alzheimer\u2019s Disease"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/175588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T17:52:30Z","timestamp":1664646750000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/175588\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":108,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,1,15]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527318666191011145941","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,15]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-06-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}